ARDS (Acute Respiratory Distress Syndrome)Real World Study
Investigational drug(s) / intervention(s)
No Intervention: Observational Cohort
No Intervention: Observational Cohort: Obsercational study
Study summary
Acute Respiratory Distress Syndrome (ARDS) is a form of acute diffuse lung injury caused by various etiologies, which rapidly progresses to acute respiratory failure. It is characterized by a sudden onset and severe clinical course. Globally, ARDS affects approximately 3 million individuals each year, accounting for about 10% of admissions to intensive care units (ICUs). Due to the lack of specific pharmacological therapies, mechanical ventilation remains the mainstay of treatment. Therefore, identifying and analyzing prognostic factors for ARDS patients is of great significance for improving patient outcomes and reducing the incidence of poor prognosis.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Patients with underlying diseases associated with high risk of ARDS, including but not limited to: sepsis, pneumonia, multiple trauma, pulmonary contusion, inhalation injury, massive blood transfusion, other high-risk conditions, or other factors causing excessive respiratory drive.
* Patients meeting the inclusion criteria for a high-risk ARDS population.
* Patients (or legal representatives) who have provided a signed and dated informed consent form.
Exclusion Criteria:
* Age under 18 years.
* HIV infection.
* Known immunodeficiency disorders (e.g., leukemia, common variable immunodeficiency, etc.).
* History of solid organ or bone marrow transplantation.
* Receiving treatment with G-CSF or GM-CSF.
* Patients with a decision to withdraw from active treatment.
Primary outcome measure(s)
Mortality — Day 28 after ARDS diagnosis Clinical observation
Mortality — Day 60 after ARDS diagnosis Clinical observation
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.